Table 3.
Medication
| All n = 1005 |
Northern Taiwan n = 576 |
Central Taiwan n = 150 |
Southern Taiwan n = 238 |
Eastern Taiwan n = 41 |
p | |
|---|---|---|---|---|---|---|
| Antiplatelet, n (%) | 913 (90.8) | 517 (89.8) | 137 (91.3) | 220 (92.4) | 39 (95.1) | 0.477 |
| Aspirin, n (%) | 478 (47.6) | 269 (46.7) | 60 (40.0) | 132 (55.5) | 17 (41.5) | 0.017 |
| Clopidogrel, n (%) | 463 (46.1) | 265 (46.0) | 86 (57.3) | 89 (37.4) | 23 (56.1) | 0.001 |
| Ticagrelor, n (%) | 15 (1.5) | 8 (1.4) | 1 (0.7) | 3 (1.3) | 3 (7.3) | <0.001 |
| Prasugrel, n (%) | 1 (0.1) | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) | 0.358 |
| Ticlopidine, n (%) | 13 (1.3) | 13 (2.3) | 0 (0) | 0 (0) | 0 (0) | 0.633 |
| Cilostazol, n (%) | 565 (56.2) | 323 (56.1) | 94 (62.7) | 125 (52.5) | 23 (56.1) | <0.001 |
| ACEi/ARB, n (%) | 397 (39.5) | 284 (49.3) | 24 (16.0) | 82 (34.5) | 7 (17.1) | <0.001 |
| Beta blocker, n (%) | 390 (38.8) | 211 (36.6) | 64 (42.7) | 91 (38.2) | 24 (58.5) | 0.031 |
| Anticoagulant, n (%) | 270 (26.9) | 120 (20.8) | 66 (44.0) | 69 (29.0) | 15 (36.6) | <0.001 |
| Rivaroxaban (2.5 mg) | 131 (13.0) | 55 (9.5) | 30 (20) | 40 (18) | 4 (9.8) | <0.001 |
| Statin, n (%) | 548 (54.5) | 342 (59.4) | 65 (43.3) | 120 (50.4) | 21 (51.2) | <0.002 |
| Antidiabetic agents, n (%) | 639 (63.6) | 397 (68.9) | 60 (40.0) | 150 (63.0) | 32 (78.0) | <0.001 |
| SGLT2-I, n (%) | 102 (10.1) | 81 (14.1) | 2 (1.3) | 13 (5.5) | 6 (14.6) | <0.001 |
| GLP-1 receptor agonist, n (%) | 16 (1.6) | 14 (2.4) | 0 (0.0) | 1 (0.4) | 1 (2.4) | 0.063 |
ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; GLP-1 receptor agonist = glucagon-like peptide-1 receptor agonists; SGLT2-I = sodium-glucose transport protein 2 inhibitor.